Authors
Takaya Komori, Eiji Nakano, Yukiko Kiniwa, Shoichiro Mori, Sotaro Yamamoto, Hiroshi Kato, Shusuke Yoshikawa, Koji Yoshino, Megumi Aoki, Tatsuya Takenouchi, Takuya Maeda, Keijun Yoshino, Shuichi Ohe, Kenta Nakama, Hideyuki Ishikawa, Yoshiyuki Nakamura, Toshihiro Takai, Takamichi Ito, Hiroshi Kitagawa, Hiraku Kokubu, Naohito Hatta, Takeru Funakoshi, Toshihiko Hoashi, Takayuki Suyama, Susumu Fujiwara, Mamiko Masuzawa, Hiroshi Uchi, Takuya Miyagawa, Soichiro Kado, Yuki Yamamoto, Jun Asai, Junji Kato, Taku Maeda, Natsuki Baba, Yukihiko Kato, Kohei Oashi, Takeo Maekawa, Shunichi Jinnai, Aya Nishizawa, Ko Kagoyama, Atsushi Otsuka, Katsuhiko Nishihara, Dai Ogata, Kenjiro Namikawa, Yasuhiro Nakamura, Shigeto Matsushita
Published in
The Journal of dermatology. Jul 06, 2026. Epub Jul 06, 2026.
Abstract
Nail apparatus melanoma (NAM) is a biologically and clinically distinct subtype of melanoma; however, the efficacy of adjuvant interferon (IFN) therapy in this population remains unclear. We conducted a multicenter retrospective study to compare adjuvant IFN-β (adj-IFN) with observation (OBS) in patients with resected stage IIB, IIC, or III NAM. We analyzed 282 Japanese patients treated at 42 institutions between 2014 and 2024. Recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were co-primary outcomes, and overall survival (OS) was a secondary outcome. Survival outcomes were assessed using Kaplan-Meier analyses and Cox multivariable proportional hazards models. To minimize the differences of baseline characteristics between the two groups, propensity score matching (PSM) was applied. In multivariable Cox analyses, adj-IFN showed improved RFS (HR 0.67, 95% CI 0.45-0.998, p = 0.049), while no statistically significant benefits were observed for DMFS (HR 0.66, 95% CI 0.42-1.01, p = 0.06) or OS (HR 0.85, 95% CI 0.54-1.35, p = 0.50) compared with OBS. After PSM (71 patients per group), survival outcomes were comparable between the two groups, with no statistical significance in RFS (HR 0.71, 95% CI 0.45-1.12, p = 0.14), DMFS (HR 0.73, 95% CI 0.44-1.20, p = 0.22), or OS (HR 1.01, 95% CI 0.58-1.78, p = 0.96). In conclusion, no significant survival advantage of adj-IFN over observation was demonstrated in the matched cohort. Although a borderline association with improved RFS was observed in the overall cohort, this finding did not translate into consistent benefit across endpoints. Further prospective evidence, including the final results of the randomized phase III trial (JCOG1309, J-FERON), is required to clarify the clinical role of adj-IFN in NAM.
PMID:
42410902
Bibliographic data and abstract were imported from PubMed on 07 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0